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Abstract
Severe sepsis and septic shock are among the leading causes of mortality in the intensive care unit. Over a decade
ago, early goal-directed therapy (EGDT) emerged as a novel approach for reducing sepsis mortality and was
incorporated into guidelines published by the international Surviving Sepsis Campaign. In addition to requiring
early detection of sepsis and prompt initiation of antibiotics, the EGDT protocol requires invasive patient monitoring
to guide resuscitation with intravenous fluids, vasopressors, red cell transfusions, and inotropes. The effect of these
measures on patient outcomes, however, remains controversial. Recently, three large randomized trials were
undertaken to re-examine the effect of EGDT on morbidity and mortality: the ProCESS trial in the United States, the
ARISE trial in Australia and New Zealand, and the ProMISe trial in England. These trials showed that EGDT did not
significantly decrease mortality in patients with septic shock compared with usual care. In particular, whereas early
administration of antibiotics appeared to increase survival, tailoring resuscitation to static measurements of central
venous pressure and central venous oxygen saturation did not confer survival benefit to most patients. In the
following review, we examine these findings as well as other evidence from recent randomized trials of goaldirected resuscitation. We also discuss future areas of research and emerging paradigms in sepsis trials.

Introduction
The Italian philosopher Niccolo Machiavelli wrote in his
classic treatise The Prince, ‘a hectic fever, in its beginning, is difficult to recognize but easy to cure; in the
course of time, it becomes easy to recognize but difficult
to cure’. Five centuries later, his insightful observation
remains largely true for patients with sepsis. With over
750,000 cases documented in the United States each
year, severe sepsis and septic shock are among the leading causes of mortality in critically ill patients and cost
the health-care system nearly $17 billion annually [1, 2].
The incidence of sepsis has increased over the last two
decades, a trend likely driven by aging patient populations, the emergence of drug-resistant pathogens, and
increased use of immunosuppressive drugs [3, 4]. Mortality rates remain high and range from 10 % to 50 %
despite advances in critical care medicine [5, 6].
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Although our understanding of the pathophysiology of
sepsis has significantly improved since the 1970s,
current treatment options continue to focus primarily
on antibiotics and supportive care. An influential study
by Rivers and colleagues [7] in 2001 introduced a novel
treatment protocol called early goal-directed therapy
(EGDT), which was shown to increase survival among
patients with septic shock at a single institution. The
EGDT protocol comprised a set of tasks to be completed
within the first 6 hours of presentation, including the
placement of a central venous catheter to monitor
hemodynamic variables during fluid resuscitation. Resuscitation was titrated to specific targets of central venous
pressure (CVP), mean arterial pressure (MAP), and
central venous oxygen saturation (ScvO2). In 2004, this
approach was adopted by the international Surviving
Sepsis Campaign (SSC) and incorporated into sepsis care
‘bundles’ that continue to be used in the intensive care
unit (ICU) [8].
Although there is broad consensus that early diagnosis
of sepsis and prompt initiation of antibiotics improve
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patient survival, methods of initial resuscitation and
hemodynamic monitoring remain controversial [9, 10].
Previous studies have shown that CVP is a poor marker
of fluid responsiveness in critically ill patients [11]. Furthermore, although central venous catheters may offer
valuable information during resuscitation, they can result
in complications such as pneumothorax and infection in
over 15 % of patients [12]. The debate was recently revisited with the publication of randomized controlled trials
of EGDT that failed to replicate positive findings of the
original study by Rivers and colleagues. This new evidence
may have significant implications for future iterations of
SSC guidelines and clinical practice. In the following review, we discuss current evidence for early goal-directed
resuscitation of patients with septic shock as well as novel
areas of research.

Pathophysiology of septic shock
The American College of Chest Physicians and Society
of Critical Care Medicine have established clinical criteria for systemic inflammatory response syndrome, sepsis, severe sepsis, and septic shock (Table 1) [13]. The
pathogenic sequence of sepsis begins with the growth of
microorganisms at a site of infection, most commonly in
the lungs, abdomen, or urinary tract. The infection either spreads into the bloodstream and results in positive
blood cultures or grows locally and induces factors that
stimulate the release of endogenous mediators of systemic inflammation [14]. These mediators can have a
significant effect on the vasculature and heart, ultimately
Table 1 Diagnostic criteria for sepsis
Diagnosis

Clinical criteria

Systemic inflammatory
response syndrome (SIRS)

Two or more of the following:
- Fever (core temperature of more than
38 °C) or hypothermia (core temperature
of less than 36 °C)
- Heart rate of more than 90 beats per
minute
- Respiratory rate of more than 20 breaths
per minute or partial pressure of carbon
dioxide in arterial blood (PaCO2) of less
than 32 mm Hg
- Leukocytosis (white-cell count of more
than 12,000 cells/μl) or leukopenia
(white-cell count of less than 4,000
cells/μl) or more than 10 % immature
forms (bands)

Sepsis

Confirmed infection and at least two
SIRS criteria

Severe sepsis

Sepsis and organ dysfunction as evidenced
by arterial hypoxemia, lactic acidosis,
oliguria, altered mental status, and so on

Septic shock

Sepsis and hypotension refractory to
fluid resuscitation
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manifesting as hypotension, systemic hypoperfusion, and
progressive failure of multiple organs.
Hypotension in sepsis occurs due to peripheral vasodilation and redistribution of intravascular fluid. Vasodilation
is thought to result from the release of vasoactive mediators produced by vascular endothelial cells, including
prostacyclin and nitric oxide [15, 16]. Inflammatory cytokines disrupt endothelial cell junctions, causing increased
capillary permeability and fluid shift into the extravascular
space. The overall effect of these changes is tissue hypoperfusion and organ dysfunction, although cardiac output
is usually preserved or increased. Occasionally, sepsis can
depress the myocardium, causing refractory distributive
and cardiogenic shock [17].
A central goal in the treatment of septic shock, therefore, is the maintenance of adequate tissue perfusion
with hemodynamic support, which includes intravenous
fluid resuscitation and administration of vasopressors, inotropes, and packed red blood cells. This general approach
is predicated upon the theory that organ dysfunction
results from intravascular volume depletion, peripheral
vasodilation, and myocardial depression. A growing body
of evidence suggests that impairment of the microvascular network may also have key pathogenic roles
(Fig. 1) [18–20]. However, few studies have examined
the physiologic effects of intravenous fluid resuscitation
beyond 30 to 60 minutes post-administration, and the
effects of fluid bolus therapy on microcirculation remain
poorly understood [21].

Initial management
The SSC advocates early recognition of septic shock and
initiation of empiric antibiotics within the first hour of
treatment. The SSC also recommends obtaining at least
two blood cultures prior to initiation of antibiotics. This
recommendation is based on data from a retrospective
study by Kumar and colleagues [22], which showed that
each hour delay in the administration of appropriate
antibiotics was associated with a 7.6 % increase in mortality. Other observational studies have provided similar
evidence of the survival benefit conferred by appropriate
antimicrobial therapy [23]. Despite a lack of evidence
from prospective randomized trials, few experts would
argue against the use of these measures to identify and
control the source of infection in sepsis [24].
Guidelines from the SSC published in 2013 also recommend goal-directed resuscitation during the first 6 hours
of septic shock (Fig. 2). In this approach, treatment with
intravenous fluids is titrated to specific endpoints, including CVP of 8 to 12 mm Hg and ScvO2 of at least 70 %.
The SSC recommends placing a central venous catheter
to monitor these variables and using a minimum of 30 ml
per kg of fluids during initial resuscitation. Other goals of
resuscitation include the use of vasopressor therapy to
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Fig. 1 Microcirculatory dysfunction in sepsis. The microvascular
network undergoes functional and structural changes during
inflammatory states such as sepsis and may have a key role in organ
dysfunction. Changes include dilation of arterioles, microvascular
thrombosis, increased adhesion of leukocytes in venules, and
increased vascular permeability. These alterations result in impaired
microcirculatory blood flow and tissue perfusion, ultimately leading
to organ failure. Techniques for measuring microcirculatory flow
in vivo have been previously described but these tools have not yet
been rigorously tested for use in patients with sepsis

achieve an MAP of at least 65 mm Hg in patients with
refractory hypotension as well as inotropic therapy in
patients with low cardiac output. In patients with ScvO2
persistently below 70 % during the first 6 hours, the SSC
advocates the use of packed red blood cell transfusions
with a target hematocrit of at least 30 %.
These recommendations are based primarily on evidence from the 2001 trial by Rivers and colleagues,
which showed that EGDT reduced the absolute risk of
in-hospital mortality by 16 %. Dozens of reports since
the trial by Rivers and colleagues have shown improved
patient outcomes with EGDT [25–46]. However, the majority of these were non-randomized studies and thus
prone to selection bias and confounding variables [47].
Furthermore, the bundled approach of EGDT precludes
identification of which elements of the protocol are primarily responsible for reductions in mortality reported
in clinical trials.
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Fig. 2 Early goal-directed therapy. During the first 6 hours of
septic shock, the early goal-directed therapy protocol requires
the placement of a central venous catheter with an oximetric
port for continuous monitoring of central venous pressure (CVP) and
central venous oxygen saturation (ScvO2). Resuscitation with intravenous
fluids, vasopressors, and packed red blood cells is titrated to specific
end-points, including CVP of 8 to 12 mm Hg, mean arterial pressure
(MAP) of at least 65 mm Hg, and ScvO2 of at least 70 %. Inotropic
therapy is recommended in patients with low cardiac output despite
adequate volume and MAP. Recent controlled clinical trials have
challenged the efficacy of this approach for reducing mortality among
patients with septic shock. HCT hematocrit

Goals of early goal-directed therapy: central
venous pressure and central venous oxygen
saturation
Recently, three large randomized controlled trials enrolling a total of 4,183 patients were completed to reexamine the effect of early goal-directed resuscitation on
outcomes in patients with septic shock: the Protocolized
Care for Early Septic Shock (ProCESS) trial in the United
States, the Australasian Resuscitation in Sepsis Evaluation
(ARISE) trial, and the Protocolised Management of Sepsis
(ProMISe) trial in England (Table 2). Each trial used
inclusion criteria similar to the original study by Rivers
and colleagues and was powered to detect a 6 % to 8 %
absolute mortality reduction [48].
The ProCESS trial enrolled patients drawn from 31
academic hospitals in the United States who were diagnosed with septic shock [49]. Patients were randomly
assigned to one of three treatment groups: EGDT with
continuous monitoring of CVP and ScvO2, protocolized
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Table 2 Randomized trials of early goal-directed therapy for patients with septic shock
Trial

Study setting

Sample size Baseline characteristics of patients receiving EGDT
APACHE II score Lactate, mmol/l Source of sepsis

EGDT in the first 6 hours

Mortality

Total fluids, l Vasopressor Red cell
Inotropic therapy, % EGDT vs. usual care, %
therapy, % transfusion, %

Rivers et al. [7] Single center in USA

263

21.4 ± 6.9

7.7 ± 4.7

38.5 % lungs, 25.6 % 4.9 ± 2.9
urinary, 35.9 % other

27.4

64.1

13.7

44.3 vs. 56.9a (P = 0.03)

ProCESS [49]

31 centers in USA

1,341

20.8 ± 8.1

4.8 ± 3.1

31.9 % lungs, 22.8 % 2.8 ± 1.9
urinary, 45.3 % other

54.9

14.4

8.0

21.0 vs. 18.9a (P = 0.83)

ARISE [50]

51 centers in Australia 1,591
and New Zealand

15.4 ± 6.5

6.7 ± 3.3

36.5 % lungs, 18.7 % 2.5 ± 1.2
urinary, 44.8 % other

66.6

13.6

15.4

18.6 vs. 18.8b (P = 0.90)

ProMISe [52]

56 centers in England 1,251

18.7 ± 7.1

7.0 ± 3.5

36.5 % lungs, 17.3
2.2 ± 1.4
urinary, 46.2 % other

53.3

8.8

18.1

29.5 vs. 29.2b (P = 0.90)

The Protocolized Care for Early Septic Shock (ProCESS), Australasian Resuscitation in Sepsis Evaluation (ARISE), and Protocolised Management of Sepsis (ProMISe) trials failed to replicate positive findings of the original
trial by Rivers and colleagues [7]. The study by Rivers and colleagues was conducted at a single emergency department in a low-income community of Detroit, Michigan. It had a high control group mortality rate,
which likely reflects health problems unique to an impoverished patient population as well as delays in treatment. Still, a subgroup analysis in the ARISE trial showed that early goal-directed therapy (EGDT) did not
improve mortality in patients with increased disease severity (Acute Physiology and Chronic Health Evaluation II (APACHE II) score >25, n = 69). Control group mortality rates were markedly lower in the ProCESS, ARISE,
and ProMISe trials, which may reflect broad shifts in clinical practice over the last decade toward earlier initiation of antibiotics and vasopressor therapy as well as conservative thresholds for blood transfusion. Indeed,
the ARISE trial reported a median time of 70 minutes between initial presentation and administration of antibiotics in the EGDT group versus 67 minutes in usual care
a
Mortality at 60 days
b
Mortality at 90 days
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standard therapy that did not require continuous monitoring, and usual care. In the usual care group, patient
care was directed by clinicians acting without a standardized protocol. Patients in the three groups received
significantly different volumes of intravenous fluids
within the first 6 hours and those in the EGDT group
were most likely to receive vasopressors, inotropes, and
red cell transfusions. Despite these differences, no significant change in 60-day mortality or need for organ
support was identified.
The ARISE trial in Australia and New Zealand offered
concordant evidence [50]. Management of sepsis in
Australasia does not typically incorporate goal-directed
resuscitation protocols advocated by the SSC. Apart
from antimicrobial therapy and source control, standard
care during the first 6 hours comprises less aggressive
fluid infusions and earlier use of vasopressors than what
is recommended by SSC guidelines [51]. The ARISE
study enrolled patients drawn from 51 urban and rural
hospitals who were diagnosed with septic shock. Patients
were randomly assigned to receive either EGDT or usual
care. Measurement of CVP and ScvO2 using central
lines was strictly limited to EGDT and was not permitted
in the usual care group. Patients in the EGDT group
received significantly more fluids and were more likely
to receive vasopressors, inotropes, and red cell transfusions compared with the usual care group. However, no
significant difference in 90-day mortality, need for organ
support, or length of hospital stay was identified.
The ProMISe trial showed findings consistent with
evidence from ProCESS and ARISE and also reported on
cost-effectiveness of the EGDT protocol [52]. Patients
with septic shock were drawn from 56 hospitals in
England and were randomly assigned to receive either
a 6-hour sepsis care bundle with EGDT or usual care
that did not incorporate continuous monitoring of
CVP and ScvO2. Patients in the EGDT group received
significantly more fluids and were more likely to receive
vasopressors, inotropes, and red cell transfusions than
those in usual care. However, no significant difference in
90-day mortality was found. Compared with those receiving usual care, patients in the EGDT group had
significantly higher organ failure scores at 6 hours
and longer stays in the ICU and were more likely to
require advanced cardiovascular support. Investigators
also showed that average costs in the EGDT group were
higher than in usual care but this difference was not statistically significant.
The ProCESS, ARISE, and ProMISe trials reported
control group mortality rates that were markedly lower
compared with the original trial by Rivers and colleagues.
This likely reflects gradual improvements in intensive care
since the 1990s, including the adoption of SSC guidelines
that support early identification of sepsis and prompt
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initiation of antibiotics [53]. Indeed, patients assigned to
usual care received fluid boluses within the first 6 hours
and antibiotics prior to randomization. Titrating fluids to
CVP and ScvO2, however, did not confer survival benefit
to most patients. It remained unclear whether a subset of
patients who fail to respond to initial resuscitation may
benefit from such measures. The recent trials of EGDT
also did not address whether monitoring CVP and ScvO2
is beneficial during the initiation of mechanical ventilation
in patients with septic shock, when the risk of acute
cardiovascular collapse is increased.

Goals of early goal-directed therapy: mean
arterial pressure
In patients with hypotension despite adequate fluid repletion (defined as CVP of at least 8 to 12 mm Hg) or
evidence of cardiogenic pulmonary edema, the SSC recommends the use of vasopressors to maintain blood
pressure. The benefit of vasopressors in patients with refractory septic shock is well supported by evidence from
randomized controlled trials [54]. The SSC currently
advocates an MAP goal of 65 mm Hg during the first
6 hours of treatment. Owing to the theoretical risk of
coronary ischemia and acute renal and hepatic failure,
higher blood pressure goals are not advised, except for
patients with atherosclerosis or chronic hypertension
[55]. This recommendation is based on evidence from
observational studies and one small randomized trial by
Bourgoin and colleagues [56–60], which showed no differences in tissue oxygenation or mortality for patients
who received higher versus lower MAP targets.
In 2014, a randomized controlled trial called Sepsis
and Mean Arterial Pressure (SEPSISPAM) was conducted at 29 centers in France to re-examine high versus
low MAP goals in patients with septic shock [61]. The
trial also sought to determine whether a subgroup of
patients with chronic hypertension benefited from treatment with an MAP target of 80 to 85 mm Hg. Investigators found no significant difference in mortality between
those treated with a low versus high MAP target. They
also found that the incidence of atrial fibrillation was
significantly increased among those in the high-target
group compared with the low-target group (6.7 % versus
2.8 %, P = 0.02). Investigators showed that chronic
hypertension patients who were treated with a higher
MAP target were significantly less likely to require renal
replacement therapy but did not have increased survival
compared with the low-target group. These findings
support an MAP goal of 65 mm Hg in most patients
with septic shock and suggest that a higher MAP goal
may decrease morbidity among those with chronic
hypertension.
The optimal timing of vasopressors relative to fluid
infusion remains more controversial. Recently, a large
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multi-center observational study was undertaken in
Canada, the United States, and Saudi Arabia to address
this question [62]. In a retrospective analysis of 2,849
patients with septic shock, investigators found that mortality was lowest when vasopressors were delayed by
1 hour and infused from hours 1 to 6 following onset of
shock. These findings are consistent with those of other
retrospective cohort studies that support the early initiation of vasopressors [63, 64]. This approach may decrease
the volume of fluids necessary to maintain blood pressure.
Indeed, patients in the recent ProCESS, ARISE, and
ProMISe trials were more likely to receive vasopressors
and required less fluids than patients in the original study
by Rivers and colleagues (Table 2). Still, prospective randomized trials are needed to elucidate the optimal
timing of vasopressors and volume of fluids during initial
resuscitation.

Goals of early goal-directed therapy: hemoglobin
concentration
In the original trial by Rivers and colleagues, packed red
blood cell transfusions were used as part of the EGDT
protocol and subsequently became one of the key components of sepsis care bundles advocated by the SSC.
The SSC recommends using blood transfusions during
the first 6 hours of septic shock, but guidelines for when
to initiate therapy remain ambiguous and suggest that
most patients are eligible for a liberal transfusion threshold. Goals of transfusion include a hematocrit of at least
30 % or a hemoglobin concentration of between 7.0 and
9.0 g/dl. This recommendation is based on evidence
from the Transfusion Requirements in Critical Care
(TRICC) trial conducted in 1999 [65]. The TRICC trial
was a randomized study that enrolled 838 critically ill
patients, among whom only 16.7 % had septic shock.
Investigators showed that a liberal transfusion threshold
of 10.0 to 12.0 g/dl did not significantly improve mortality compared with a conservative threshold of 7.0 to
9.0 g/dl.
Recently, the Transfusion Requirements in Septic
Shock (TRISS) trial re-examined transfusion thresholds
in patients with sepsis [66]. This randomized study enrolled 998 patients from 32 ICUs in Scandinavia and
showed that a hemoglobin threshold for transfusion of
7.0 g/dl resulted in similar rates of mortality, ischemic
events, and use of life support in comparison with a
threshold of 9.0 g/dl. The conservative approach also
decreased the use of blood products by 50 %. In the
ProCESS, ARISE, and ProMISe trials, patients receiving
EGDT were transfused according to goals described in
the original trial by Rivers and colleagues: a target
hematocrit of at least 30 % if ScvO2 remained below 70
% despite appropriate fluid resuscitation. As a result,
patients receiving EGDT were about twice as likely to
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receive transfusions in comparison with those receiving
usual care but this did not improve mortality. These studies collectively suggest that a conservative transfusion
threshold of 7.0 g/dl is safe for the majority of patients
with septic shock.

Alternatives to central venous pressure and
central venous oxygen saturation
One of the key challenges of treating shock is the measurement of intravascular volume and oxygen delivery
during fluid bolus therapy. This is of particular importance in patients with sepsis, who are at high risk of fluid
overload. Previous studies have estimated that only 50 % of
hemodynamically unstable patients are fluid-responsive,
highlighting the need for accurate measurement of volume
status [67, 68]. Physical examination and chest radiography
are simple methods of assessing volume but are statistically
insensitive and unreliable. Static measurements of CVP and
pulmonary capillary wedge pressure can be used but also
have low sensitivity and specificity for predicting fluid
responsiveness [11, 69]. This is likely due to the nonlinear
relationship between volume and pressure, which results
from variable compliance of the cardiovascular system. The
use of ScvO2 as an indirect marker of cardiac output and
tissue oxygenation is also controversial. Previous studies
have shown that ScvO2 does not always approximate mixed
venous oxygen saturation (SvO2), a more accurate marker
of total body oxygen consumption [70].
This has prompted the development of alternative
methods of monitoring fluid responsiveness in the ICU.
Dynamic indices such as variation in stroke volume,
pulse pressure, and the diameter of inferior vena cava
(IVC) offer the advantage of real-time assessment of
hemodynamic status. However, measurement of stroke
volume and pulse pressure variation is typically reserved
for patients who are receiving mechanical ventilation
[71, 72]. The IVC diameter can be measured in spontaneously breathing patients by ultrasound but provides
only an indirect assessment of CVP [73]. Other techniques such as the passive leg-raise maneuver and minifluid challenge have thus been proposed [74, 75]. The
mini-fluid challenge requires a bolus of 100 to 500 ml of
crystalloids infused over 10 to 30 minutes, whereas the
passive leg-raise acts as a ‘self’ fluid challenge that increases cardiac preload. In these techniques, an ultrasound cardiac output monitor is used to estimate a
patient’s fluid responsiveness from position on the FrankStarling curve. A patient is considered fluid-responsive if
cardiac output increases by at least 10 % to 15 % after the
fluid challenge (Fig. 3).
Several ongoing trials are investigating the potential role
of real-time monitoring of cardiac output to guide fluid resuscitation in sepsis. A Goal-Oriented Non-Invasive Sepsis
Trial (AGONIST) is a randomized study in Singapore that
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Fig. 3 Measuring fluid responsiveness by cardiac ultrasound. A
patient is considered fluid-responsive if left ventricular function falls
along the ascending portion of the Frank-Starling curve. Additional
fluids given above this zone do not increase cardiac output and
worsen the risk of volume overload. Measurement of stroke volume
and cardiac output by Doppler ultrasound may allow more accurate
estimation of fluid responsiveness in patients receiving intravenous
fluid therapy

will investigate the passive leg-raise maneuver and
ultrasound cardiac output monitor for patients with
sepsis. The Bioimpedance Analysis in Septic Intensive
Care Unit Patients (BIOVISION) is testing another
noninvasive method of volume assessment. Bioimpedance analysis has been used for several decades to
measure volume status and guide fluid management
in patients receiving hemodialysis [76]. In this technique, a small alternating current is passed between
electrodes on the hand and foot. The measured drop
in voltage reflects resistance to electrical flow or ‘impedance’, which is inversely proportional to total body
water.
The role of microcirculation in shock and resuscitation
is another potential area of future research. Tissue perfusion and oxygenation are commonly assessed via measurements of arterial lactate concentration. However,
previous randomized trials of lactate-guided resuscitation have offered conflicting evidence of survival benefit,
and the SSC does not currently advocate a specific goal
for lactate reduction during initial treatment of septic
shock [77, 78]. Direct observation of microcirculation
may offer more accurate assessments of vital organ
blood flow and oxygenation [79, 80]. Unfortunately,
measurement of microvascular flow is limited to easily
accessible organs such as the skin and tongue, and there
is considerable inter-operator variation with currently
available techniques.
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Emerging paradigms in sepsis trials
In a subset analysis of the ARISE trial, investigators
showed that EGDT did not improve mortality in patients
with increased severity of illness [50]. The quantification
of disease severity in critically ill patients, however,
remains a significant challenge in clinical trials and may
confound comparative analyses of treatment effect. Scoring systems such as the Acute Physiology and Chronic
Health Evaluation are commonly used but were not originally designed for stratifying patients in clinical trials
and have been validated in only the first 24 to 48 hours
of hospital admission. These population-based statistical
models predict ICU mortality but do not accurately
reflect pathology in individual patients [81]. Disease
severity would likely be better characterized by using
molecular diagnostics. Unfortunately, whereas dozens of
sepsis biomarkers have been proposed, none has demonstrated sufficient specificity and sensitivity for clinical
use [82]. Recent studies suggest that gene expression
profiling might offer an alternative approach to stratifying patients in clinical trials [83].
Another barrier to evidence-based sepsis care arises
from limitations inherent in traditional randomized
controlled trials, which are ill equipped for answering clinical questions in patients with evolving disease states and
myriad treatment interventions. Dynamic ‘adaptive’ trial
designs have recently emerged as an alternative for studies
in critical care. As data accumulate in an adaptive trial,
the allocation ratio is changed to favor the treatment
group that appears superior. This approach allows investigators to achieve statistical significance with smaller
samples and test multiple treatment options that are
modifiable as disease severity changes among participants
[84]. Adaptive clinical trials have been used previously in
many oncology studies and may offer greater safety and
efficiency than classic randomized trials [85].
Conclusions
Conventional management that focuses on early antibiotics and targeted resuscitation has contributed to improvements in survival of patients with septic shock over
the last decade. New evidence from the ProCESS, ARISE
and PRoMISe trials, however, suggests that structured
‘early goal-directed resuscitation’ with routine placement
of a central venous catheter, monitoring of mixed venous
oxygen saturation and aggressive red cell transfusion does
not improve outcomes in most patients with septic shock.
The nuances of fluid and vasopressor administration in
early septic shock remain incompletely defined. Further,
development and validation of practical methods for accurately assessing optimal fluid administration is needed.
Future studies that seek to address these issues will likely
benefit from emerging novel techniques, including molecular diagnostics and adaptive trial designs.
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